MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Organon & Co

Closed

SectorHealthcare

14.74 4.39

Overview

Share price change

24h

Current

Min

13.88

Max

14.75

Key metrics

By Trading Economics

Income

-250M

109M

Sales

10M

1.6B

P/E

Sector Avg

4.357

63.778

EPS

0.9

Dividend yield

7.72

Profit margin

6.847

Employees

10,000

EBITDA

-64M

338M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+28.95% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

7.72%

2.39%

Next Earnings

1 May 2025

Next Dividend date

12 Jun 2025

Next Ex Dividend date

9 May 2025

Market Stats

By TradingEconomics

Market Cap

-304M

3.7B

Previous open

10.35

Previous close

14.74

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Organon & Co Chart

Past performance is not a reliable indicator of future results.

Related News

2 Apr 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 Apr 2025, 22:50 UTC

Major Market Movers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 Apr 2025, 21:08 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 Apr 2025, 21:00 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 Apr 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 Apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Apr 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 Apr 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 Apr 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Apr 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 Apr 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Apr 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 Apr 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 Apr 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 Apr 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 Apr 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 Apr 2025, 22:43 UTC

Top News
Acquisitions, Mergers, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 Apr 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 Apr 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 Apr 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 Apr 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Apr 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 Apr 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 Apr 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 Apr 2025, 20:53 UTC

Earnings

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 Apr 2025, 20:52 UTC

Earnings

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Comparison

Price change

Organon & Co Forecast

Price Target

By TipRanks

28.95% upside

12 Months Forecast

Average 19.2 USD  28.95%

High 24 USD

Low 16 USD

Based on 6 Wall Street analysts offering 12 month price targets forOrganon & Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

1

Buy

3

Hold

2

Sell

Technical Score

By Trading Central

N/A / 15.77Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.